Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

NCT00425204 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Solid Tumors
Advanced Renal Cell Carcinoma

Interventions

DRUG: Panitumumab (ABX-EGF)

Sponsor

Amgen